Clinuvel Pharmaceuticals Limited (CUV:ASX)
$30.30
-0.21 (-0.69%)
MCAP $1.497B
Last trade 16.10pm 16/04/2021
20mins delayed
Latest Announcements
12/04/2021CUVClinuvel Pharmaceuticals Limited
1,447
MCap
01/04/2021CUVClinuvel Pharmaceuticals Limited
1,193
MCap
31/03/2021CUVClinuvel Pharmaceuticals Limited
1,893
MCap
24/03/2021 Price SensitivePSCUVClinuvel Pharmaceuticals Limited
24/03/2021CUVClinuvel Pharmaceuticals Limited
10/03/2021CUVClinuvel Pharmaceuticals Limited
05/03/2021CUVClinuvel Pharmaceuticals Limited
4,101
MCap
03/03/2021CUVClinuvel Pharmaceuticals Limited
1,270
MCap
Company Overview
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company. The Company is focused on developing and providing treatments for patients with a range of severe genetic and skin disorders. It is focused on developing and commercializing SCENESSE as a preventative therapy to photo-protect patients with erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination therapy with narrowband ultraviolet B (NB-UVB) phototherapy for patients with vitiligo. Its pipeline includes research and development into a pediatric formulation of SCENESSE; SCENESSE for adult vitiligo patients; SCENESSE for adult patients with VP; products based on melanocortin analogues CUV9900 and Parvysmelanotide (VLRX001) and a range of over the counter products for general photoprotective application.
